Hacettepe University, Faculty of Pharmacy, Department of Biochemistry, 06100 Ankara, Turkey.
Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, 06100 Ankara, Turkey.
Int J Pharm. 2024 Nov 15;665:124715. doi: 10.1016/j.ijpharm.2024.124715. Epub 2024 Sep 14.
Postmastectomy radiotherapy causes capsular contracture due to fibroproliferation of the capsular tissue around the implant. In fibrosis, unlike normal wound healing, structural and functional disorders are observed in the tissues caused by excessive/irregular accumulation of extracellular matrix proteins. It has been reported that transforming growth factor-β3 (TGF-β3) prevents and reverses fibrosis in various tissues or provides scarless healing with its antifibrotic effect. Additionally, TGF-β3 has been shown to reduce fibrosis in radiotherapy-induced fibrosis syndrome. However, no study in the literature investigates the effects of exogenously applied TGF-β3 on capsular contracture in aesthetic or reconstructive breast implant application. TGF-β3, which has a very short half-life, has low bioavailability with parenteral administration. Within the scope of this study, free TGF-β3 was loaded into the nanoparticles to increase its low bioavailability and extend its duration of action by providing controlled release. The aim of this study is to investigate the preventive/improving effects of radiation induced capsular contracture using chitosan film formulations containing TGF-β3 loaded poly(lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG) nanoparticles in implant-based breast reconstruction. In the characterization studies of nanoparticles, the particle size and zeta potential of the TGF-β3-loaded PLGA-b-PEG nanoparticle formulation selected to be used in the treatment group were found to be 123.60 ± 2.09 nm and -34.87 ± 1.42 mV, respectively. The encapsulation efficiency of the formulation was calculated as 99.91 %. A controlled release profile was obtained in in vitro release studies. Chitosan film formulations containing free TGF-β3 or TGF-β3-loaded PLGA-b-PEG nanoparticles were used in in vivo studies. In animal studies, rats were randomly distributed into 6 groups (n = 8) as sham, implant, implant + radiotherapy, implant + radiotherapy + chitosan film containing unloaded nanoparticles, implant + radiotherapy + chitosan film containing free TGF-β3, implant + radiotherapy + chitosan film containing TGF-β3 loaded nanoparticle. In all study groups, a 2 cm incision was made along the posterior axillary line at the thoracic vertebral level in rats to reach the lateral edge of the latissimus dorsi. The fascial attachment to the chest wall was then bluntly dissected to create a pocket for the implants. In the treatment groups, the wound was closed after films were placed on the outer surface of the implants. After administering prophylactic antibiotics, rats were subjected to irradiation with 10 Gy photon beams targeted to each implant site. Each implant and the surrounding excised tissue were subjected to the necessary procedures for histological (capsule thickness, cell density), immunohistochemical, and biochemical (α-SMA, vimentin, collagen type I and type III, TGF-β1 and TGF-β3: expression level/protein level) examinations. It was determined that the levels of TGF-β1 and TGF-β3 collagen type III, which decreased as a result of radiotherapy, were brought to the control level with free TGF-β3 film and TGF-β3 nanoparticle film formulations. Histological analyses, consistent with biochemical analyses, showed that thick collagen and fibrosis, which increased with radiotherapy, were brought to the control level with free TGF-β3 film and TGF-β3 nanoparticle film treatments. In biochemical analyses, the decrease in thick collagen was compatible with the decrease in the collagen type I/type III ratio in the free TGF-β3 film and TGF-β3 nanoparticle film groups. Changes in protein expression show that TGF-β3 loaded nanoparticles are more successful than free TGF-β3 in wound healing. In line with these results and the literature, it is thought that the balance of TGF-β1 and TGF-β3 should be maintained to ensure scarless wound healing with no capsule contracture.
乳腺癌根治术后放疗会导致假体周围包膜挛缩,这是由于假体周围包膜组织的纤维增生所致。在纤维化中,与正常的伤口愈合不同,组织中会观察到结构和功能障碍,这是由于细胞外基质蛋白的过度/不规则积累所致。有报道称,转化生长因子-β3(TGF-β3)通过其抗纤维化作用,可预防和逆转各种组织中的纤维化,并提供无瘢痕愈合。此外,TGF-β3 已被证明可减少放疗诱导的纤维化综合征中的纤维化。然而,文献中没有研究表明外源性应用 TGF-β3 对美容或重建乳房假体应用中的包膜挛缩的影响。半衰期非常短的 TGF-β3 经肠胃外给药时生物利用度低。在本研究范围内,将游离 TGF-β3 载入纳米颗粒中,通过提供控制释放来增加其低生物利用度并延长作用持续时间。本研究的目的是研究壳聚糖膜配方中负载 TGF-β3 的聚乳酸-共-羟基乙酸-b-聚乙二醇(PLGA-b-PEG)纳米颗粒在基于假体的乳房重建中对放疗诱导的包膜挛缩的预防/改善作用。在纳米颗粒的特征研究中,发现治疗组中使用的负载 TGF-β3 的 PLGA-b-PEG 纳米颗粒制剂的粒径和 Zeta 电位分别为 123.60 ± 2.09nm 和-34.87 ± 1.42mV。该制剂的包封效率计算为 99.91%。在体外释放研究中获得了受控释放曲线。在体内研究中使用了负载游离 TGF-β3 或负载 TGF-β3 的 PLGA-b-PEG 纳米颗粒的壳聚糖膜配方。在动物研究中,大鼠随机分为 6 组(n=8):假手术组、假体组、假体+放疗组、假体+放疗+载有未负载纳米颗粒的壳聚糖膜组、假体+放疗+载有游离 TGF-β3 的壳聚糖膜组、假体+放疗+载有负载 TGF-β3 的纳米颗粒的壳聚糖膜组。在所有研究组中,在大鼠胸腰椎水平沿腋后线做 2cm 切口,到达背阔肌外侧缘。然后钝性解剖胸壁筋膜附着处,为植入物创建一个口袋。在治疗组中,在将膜放置在植入物的外表面后闭合伤口。在给予预防性抗生素后,用 10Gy 光子束照射每个植入物部位。对每个植入物和周围切除的组织进行必要的程序,以进行组织学(囊厚度、细胞密度)、免疫组织化学和生物化学(α-SMA、波形蛋白、I 型和 III 型胶原、TGF-β1 和 TGF-β3:表达水平/蛋白水平)检查。结果表明,放疗导致 TGF-β1 和 TGF-β3 水平降低,游离 TGF-β3 膜和 TGF-β3 纳米颗粒膜制剂可使 TGF-β3 水平恢复到对照水平。与生物化学分析一致的组织学分析表明,游离 TGF-β3 膜和 TGF-β3 纳米颗粒膜治疗可使放疗引起的厚胶原和纤维化恢复到对照水平。在生物化学分析中,厚胶原的减少与游离 TGF-β3 膜和 TGF-β3 纳米颗粒膜组中 I 型/III 型胶原比值的减少一致。蛋白质表达的变化表明负载 TGF-β3 的纳米颗粒在伤口愈合方面比游离 TGF-β3 更成功。与这些结果和文献一致,认为应维持 TGF-β1 和 TGF-β3 的平衡,以确保无包膜挛缩的无瘢痕愈合。